Join the club for FREE to access the whole archive and other member benefits.

Elamipretide: a drug to protect your eyes from AMD

07-Jul-2021

Key points from article :

Elamipretide (MTP-131; Stealth BioTherapeutics Inc) was developed to treat atrophy in age-related macular degeneration (AMD).

The changes in mitochondrial function and shapes due to damage of the phospholipid cardiolipin leads to apoptosis in AMD.

“This drug binds to the cardiolipin to stabilize the inner mitochondrial membrane structure, and allowing it to resume normal function. Thus this, offers promising treatment for geographic atrophy (GA)” says Jeffrey S. Heier, MD, Ophthalmic Consultants of Boston in Massachusetts.

The phase 1 ReCLAIM study (NCT03891875) shows the safety of elamipretide for treating intermediate AMD and GA.

Scott Cousins of Duke University, designed this study focusing on patients with noncentral GA.

The phase 2 ReCLAIM study is evaluating patients. Currently placebo-controlled trial is ongoing. The results are expected to be in 2022.

Dr. Heier presented this update at the Bascom Palmer Angiogenesis, Exudation, and Degeneration 2021 virtual conference.

Elamipritide protects your retinal cells from undergoing degeneration

Mentioned in this article:

Tap on icon for description, click on resource name for more details.

Company Representative

MD, Scientific advisor, Director of Retina Research at Ophthalmic Consultants of Boston (OCB)

Academic

Professor and Director of the Duke Center for Macular Diseases at Duke University

Company

Biopharmaceutical company focused on the discovery and commercialization of novel therapies..